Story perspectives
Canada, Australia Approve Ozempic for Diabetes-Related Kidney Disease
8/21/2025
39 6
1 of 1
Story summary
- Canada and Australia have approved Novo Nordisk's Ozempic (semaglutide) for chronic kidney disease in type 2 diabetes patients.
- Clinical trials indicate a 24% reduction in kidney-related deaths and major cardiac events.
- Australia's Therapeutic Goods Administration (TGA) approved the drug after resolving medication shortages.
- Experts advocate for wider access through the Pharmaceutical Benefits Scheme due to the drug's high costs.
